Financial Results of the Company, for the quarter 31-12-2025.
Dear Sir/Madam,This Has Reference To Our Letter Dated January 28 2026.1) The Board Has Considered And Approved The Unaudited Consolidated & Stand-Alone Financial Results Of The Company, For The Quarter Ended 31.12.2025 In Accordance With The Indian A
View original source (BSE India)Transgene Biotek Limited on 6ix
Earlier from Transgene Biotek
- Board Meeting Outcome for Outcome Of Board Meeting
- Transgene Biotek Limited. Press Release Feb 03 2026
- Declaration Under Clause 36 Of Listing Agreement With BSEPROHIBITORY ORDER NO. RRD/SRO/1166/2026/1 - SEBI
- Transgene Biotek Limited. Press Release Jan 12 2026
- Statement Of Deviation & Variation
Later from Transgene Biotek
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Compliance-57 (5): intimation after the end of quarter
- Compliance-57 (4): Prior intimation to the beginning of the quarter
- Intimation Of Non-Applicability Of Regulation 32(1) Of SEBI Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Quarter Ended On 31St March 2026.
- Transgene Biotek Limited. Press Release Apr 13 2026
Follow Transgene Biotek into a list and get an email when it puts out news.
Follow Transgene Biotek